Mankind Pharma Ltd
Mankind Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Mankind Pharma expects progressive recovery and double-digit growth in domestic sales, with specific focus on both Chronic and Acute segments. Mankind Pharma expects double-digit growth for the full year FY27, driven by sequential recovery in both Chronic and Acute segments.
From Mankind Pharma Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Mankind Pharma expects progressive recovery and double-digit growth in domestic sales, with specific focus on both Chronic and Acute segments.
- Chronic portfolio is growing strongly (15.8% growth reported), with a medium-term target to increase its share from 40% to 50%.
- Acute segment has shown steady recovery, reaching growth comparable to Indian Pharmaceutical Market (IPM) at 10.9%.
- BSV (specialty business) is expected to grow in the high teens with balanced domestic and international expansion.
- New divisions such as Vistar aim to scale lesser-focused brands, adding to future growth.
- International business is also growing strongly (29% YoY growth reported).
- Volume growth has improved to 4.7% from 2.3% last fiscal year.
2 more points from Mankind Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Mankind Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex spend in Q1 FY27 was INR 198 crores, higher than INR 127 crores in Q1 FY26.
- Capex as a percentage of revenue is 4.9%, below the guidance of 6% to 7% for FY27.
- Company has enhanced the R&D biotech facility, indicating investment in biotech capabilities.
- Addition of a biotech facility as part of strategic changes.
2 more points from Mankind Pharma Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Mankind Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Mankind Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.3K Cr, net profit ₹716 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Mankind Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Mankind Pharma Ltd Q1 FY27 results?
Mankind Pharma expects progressive recovery and double-digit growth in domestic sales, with specific focus on both Chronic and Acute segments. Mankind Pharma expects double-digit growth for the full year FY27, driven by sequential recovery in both Chronic and Acute segments.
What is Mankind Pharma Ltd share price analysis?
Mankind Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 44.1 with a market cap of ₹93,988 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma Ltd planning capital expenditure?
Capex spend in Q1 FY27 was INR 198 crores, higher than INR 127 crores in Q1 FY26.
Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.